Skip to main content
Premium Trial:

Request an Annual Quote

New Product Watch: Mar 29, 2011


BlueGnome last week launched a new version of its CytoChip Cancer array for use in high-throughput research applications.

Researchers will now be able to survey eight, 60,000-marker arrays per slide. The initial version of CytoChip Cancer, which was launched in December 2010, provided four, 180,000-marker arrays per slide. BlueGnome's arrays are manufactured by Agilent Technologies.

A BlueGnome spokesperson told BioArray News that the high-density probe coverage of genes important in cancer on the 8x60K format is the same as the 4x180K format. At the same time, the "backbone resolution" across the genome is lower. "The 4x180K has an average spacing of 20 kilobases on the backbone whereas the 8x60K has an average backbone spacing of 60 kb," she said.

The "main difference," she noted, is that the new chips enable users to run eight samples at once, using less sample material and reagents, "making it appealing to high-throughput labs and lowering the cost per sample."

Avantra Biosciences last week introduced its Path protein microarray ultra-thin nitrocellulose slides. The firm claims the substrates provide "very low background fluorescence and excellent signal-to-noise ratio."

Additionally, Avantra claims that the slides offer "excellent" stability, shelf life, and spot morphology. The slides are available in the 1x3 inch "standard slide format" and are adaptable to "all commonly used slide format microarray readers."

Avantra said the Path technology is integrated into its Q400 Biomarker Workstation, which enables researchers to perform multiplex biomarker analysis.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more